Takeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about US$200 million related to Novartis AG’s decision to withdraw a marketing application for the dry-eye drug Xiidra.
Japan’s Takeda expects US$200 mln operating loss related to Novartis’ Xiidra withdrawal
